CDXS Stock Overview
Provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Codexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.47 |
| 52 Week High | US$6.08 |
| 52 Week Low | US$1.90 |
| Beta | 2.57 |
| 1 Month Change | 16.51% |
| 3 Month Change | -42.69% |
| 1 Year Change | -31.58% |
| 3 Year Change | -76.45% |
| 5 Year Change | -77.97% |
| Change since IPO | -81.37% |
Recent News & Updates
Recent updates
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 17
ECO Synthesis Launch In 2025 Will Unlock Pharma Contracts
Mar 29 Transitioning to commercial execution with ECO Synthesis and partnerships enhances revenue growth by securing new contracts and expanding into pharma and biotech segments.Codexis, Inc. (NASDAQ:CDXS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Mar 28Estimating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jan 06Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way?
Dec 10Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors
Nov 07After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar
Jul 26Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Jul 12Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects
May 29Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Shareholder Returns
| CDXS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.4% | 2.7% | 5.3% |
| 1Y | -31.6% | -29.7% | 11.9% |
Return vs Industry: CDXS matched the US Life Sciences industry which returned -31.4% over the past year.
Return vs Market: CDXS underperformed the US Market which returned 11.2% over the past year.
Price Volatility
| CDXS volatility | |
|---|---|
| CDXS Average Weekly Movement | 14.0% |
| Life Sciences Industry Average Movement | 10.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CDXS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CDXS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 188 | Stephen Dilly | www.codexis.com |
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc. Fundamentals Summary
| CDXS fundamental statistics | |
|---|---|
| Market cap | US$207.94m |
| Earnings (TTM) | -US$74.46m |
| Revenue (TTM) | US$49.82m |
4.1x
P/S Ratio-2.7x
P/E RatioIs CDXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXS income statement (TTM) | |
|---|---|
| Revenue | US$49.82m |
| Cost of Revenue | US$62.12m |
| Gross Profit | -US$12.31m |
| Other Expenses | US$62.15m |
| Earnings | -US$74.46m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | -24.71% |
| Net Profit Margin | -149.47% |
| Debt/Equity Ratio | 58.8% |
How did CDXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 21:43 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Codexis, Inc. is covered by 20 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| J. Horwitz | Baird |
| Vishal Shah | Barclays |
| Robert Wasserman | Benchmark Company |